Aurealis Therapeutics Raises $10 Million in an Oversubscribed Series A Financing to Accelerate Phase 2 Clinical Studies in Chronic Wounds and Preclinical Development in Oncology with Its First-in-Class Technology Platform

Aurealis Therapeutics Management Team

Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for high unmet medical needs, has raised over $10 million through a Series A financing round co-led by Lynx Financial and TESI (Finnish Industry Investment Ltd) with participation of Huahai Pharmaceuticals, family offices and biotech HNWIs. The funds will be primarily used to […]

Aurealis Therapeutics announces 7.8MCHF financing to advance the chronic wound lead candidate AUP-16 to diabetic foot ulcer patients under new brand Aurealis Therapeutics AG

Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer announced 7.8MCHF funding provided by Swiss and foreign private investors, Finnvera plc, and Business Finland – the Finnish Innovation Funding Agency. The Company also confirmed the de-merger and a plan to develop and commercialize the AUP-16 under a […]